These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4860064)

  • 41. [Experiences with the live measles vaccine].
    Vivell O; Lips G
    Arch Kinderheilkd; 1967; 176(2):156-63. PubMed ID: 5592896
    [No Abstract]   [Full Text] [Related]  

  • 42. [Experiment of vaccination against measles using attenuated virus (Schwarz strain) (author's transl)].
    Trivello R; Renzulli G; Romano M; Milone G; Moschen ME
    Ann Sclavo; 1978; 20(2):113-20. PubMed ID: 742926
    [No Abstract]   [Full Text] [Related]  

  • 43. [Antibody status following live measles vaccine--3 years postvaccination].
    Schumacher H; Welbers de Liddle IB
    Dtsch Med Wochenschr; 1970 Jul; 95(31):1594-8. PubMed ID: 5431984
    [No Abstract]   [Full Text] [Related]  

  • 44. [A study of the immunologic activity of the live measles vaccine developed by the Academy of Medical Sciences of the USSR from strain EShCh].
    Voroshilova MK; Chumakov MP; Siniak KM; Ralko LP; Romanenko VF; Rodin VI; Karaseva IA; Khozinskiĭ VI; Seĭbil' VB; Zaprometova LV; Turakhodzhaeva RZ; Urin AI; Chudnaia LM
    Vopr Virusol; 1967; 12(4):415-9. PubMed ID: 5611747
    [No Abstract]   [Full Text] [Related]  

  • 45. [Immune status following the administration of anti-measles vaccines].
    Hernández Muñoz H
    Rev Clin Esp; 1968 Apr; 109(2):97-100. PubMed ID: 5739643
    [No Abstract]   [Full Text] [Related]  

  • 46. Vaccination against measles in the Canadian Arctic.
    Furesz J; Habgood M
    JAMA; 1966 Jan; 195(5):342-4. PubMed ID: 5951890
    [No Abstract]   [Full Text] [Related]  

  • 47. Five cases of measles secondary vaccine failure with confirmed seroconversion after live measles vaccination.
    Hirose M; Hidaka Y; Miyazaki C; Ueda K; Yoshikawa H
    Scand J Infect Dis; 1997; 29(2):187-90. PubMed ID: 9181657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A study of the protective effect of live measles vaccines 13 to 27 months after vaccination.
    Sejda J; Helcl J; Strauss J; Zdrazílek J; Mírovský J
    J Hyg Epidemiol Microbiol Immunol; 1968; 12(2):187-91. PubMed ID: 5752748
    [No Abstract]   [Full Text] [Related]  

  • 49. [Clinical and immunological reactions after measles vaccination with cleavage vaccine and live vaccine].
    Stehr K; Enders G; Suschke HJ; Spiess H
    Monatsschr Kinderheilkd (1902); 1970 Jun; 118(6):383-7. PubMed ID: 5523685
    [No Abstract]   [Full Text] [Related]  

  • 50. [Results of clinical trials of the superattenuated measles vaccine of the Institute Armand-Frappier].
    Davignon L; Lussier G; Quevillon M; Lavergne B; Fauvel M; Aubert D
    J Biol Stand; 1982 Oct; 10(4):347-55. PubMed ID: 6759509
    [No Abstract]   [Full Text] [Related]  

  • 51. Atypical measles in children previously immunized with attenuated measles virus vaccines.
    Cherry JD; Feigin RD; Lobes LA; Shackelford PG
    Pediatrics; 1972 Nov; 50(5):712-7. PubMed ID: 5084185
    [No Abstract]   [Full Text] [Related]  

  • 52. Determination of measles immunity after a mass immunization campaign.
    Levitt LP; Case GE; Neil JS; Casey HL; Adler P; Ferreri S; Witte JJ
    Public Health Rep (1896); 1970 Mar; 85(3):261-5. PubMed ID: 4984891
    [No Abstract]   [Full Text] [Related]  

  • 53. [Development of measles vaccination in Austria].
    Huber EG; Rannon L
    Padiatr Padol; 1973; 8(3):247-56. PubMed ID: 4715034
    [No Abstract]   [Full Text] [Related]  

  • 54. Development and characteristics of live AIK-C measles virus vaccine: a brief report.
    Makino S
    Rev Infect Dis; 1983; 5(3):504-5. PubMed ID: 6410489
    [No Abstract]   [Full Text] [Related]  

  • 55. [A comparative study of 3 different types of trivalent measles-mumps-rubella vaccine].
    Contardi I; Lusardi C; Cattaneo GG
    Pediatr Med Chir; 1992; 14(4):421-4. PubMed ID: 1461782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trivalent combined measles-mumps-rubella vaccine. Findings in clinical-laboratory studies.
    Stokes J; Weibel RE; Villarejos VM; Arguedas JA; Buynak EB; Hilleman MR
    JAMA; 1971 Oct; 218(1):57-61. PubMed ID: 4937795
    [No Abstract]   [Full Text] [Related]  

  • 57. Measles vaccine: immunity, reinfection and revaccination.
    Linnemann CC
    Am J Epidemiol; 1973 Jun; 97(6):365-71. PubMed ID: 4713932
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells.
    Just M; Berger R; Glück R; Wegmann A
    Dev Biol Stand; 1986; 65():25-7. PubMed ID: 3549399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serological survey of measles immunization with the Rimevax--RIT--vaccine in a Romanian district.
    Ciufecu E; Dincă L; Serbănescu R; Dinculescu M; Găleşanu M
    Arch Roum Pathol Exp Microbiol; 1980; 39(1):31-40. PubMed ID: 6996640
    [No Abstract]   [Full Text] [Related]  

  • 60. Response to live attenuated measles vaccine in susceptible island populations in Micronesia.
    Brown P; Basnight M; Gajdusek DC
    Am J Epidemiol; 1965 Sep; 82(2):115-22. PubMed ID: 5890043
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.